Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones

G. G. Zhanel, J. A. Karlowsky, M. H. Saunders, R. J. Davidson, D. J. Hoban, Robert Hancock, I. McLean, L. E. Nicolle

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone- containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 μg/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coil gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.

LanguageEnglish
Pages489-495
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number2
DOIs
Publication statusPublished - 1 Jan 1995

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Zhanel, G. G. ; Karlowsky, J. A. ; Saunders, M. H. ; Davidson, R. J. ; Hoban, D. J. ; Hancock, Robert ; McLean, I. ; Nicolle, L. E. / Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. In: Antimicrobial Agents and Chemotherapy. 1995 ; Vol. 39, No. 2. pp. 489-495.
@article{12b041297289412da5a52d004c3a88e1,
title = "Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones",
abstract = "Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone- containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 μg/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coil gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.",
author = "Zhanel, {G. G.} and Karlowsky, {J. A.} and Saunders, {M. H.} and Davidson, {R. J.} and Hoban, {D. J.} and Robert Hancock and I. McLean and Nicolle, {L. E.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1128/AAC.39.2.489",
language = "English",
volume = "39",
pages = "489--495",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
number = "2",

}

Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones. / Zhanel, G. G.; Karlowsky, J. A.; Saunders, M. H.; Davidson, R. J.; Hoban, D. J.; Hancock, Robert; McLean, I.; Nicolle, L. E.

In: Antimicrobial Agents and Chemotherapy, Vol. 39, No. 2, 01.01.1995, p. 489-495.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones

AU - Zhanel, G. G.

AU - Karlowsky, J. A.

AU - Saunders, M. H.

AU - Davidson, R. J.

AU - Hoban, D. J.

AU - Hancock, Robert

AU - McLean, I.

AU - Nicolle, L. E.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone- containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 μg/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coil gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.

AB - Laboratory-derived fluoroquinolone-resistant mutants were created by serially passaging wild-type Pseudomonas aeruginosa on fluoroquinolone- containing agar to obtain high-level fluoroquinolone resistance (e.g., ciprofloxacin MIC of 1,024 μg/ml). With increases of 4- to 32-fold in MICs of fluoroquinolones, these organisms demonstrated (relative to wild-type) normal morphology, resistance to fluoroquinolones only, no change in fluoroquinolone uptake, and no change in lipopolysaccharide profiles or outer membrane protein profiles. Complementation with wild-type Escherichia coil gyrA restored fluoroquinolone susceptibility, suggesting that these were gyrA mutants. After 4- to 32-fold increases in fluoroquinolone MICs (with continued passage on fluoroquinolone-containing agar) isolates demonstrated altered morphology, a multiple-antibiotic-resistant (Mar) phenotype (including cross-resistance to beta-lactams, chloramphenicol, and tetracycline), reduced fluoroquinolone uptake and altered outer membrane proteins (reductions in the 25- and 38-kDa bands as well as several bands in the 43- to 66-kDa region). Complementation with wild-type E. coli gyrA partially reduced the level of fluoroquinolone resistance by approximately 8- to 32-fold, suggesting that these mutants displayed both gyrA and non-gyrA mutations.

UR - http://www.scopus.com/inward/record.url?scp=0028796858&partnerID=8YFLogxK

U2 - 10.1128/AAC.39.2.489

DO - 10.1128/AAC.39.2.489

M3 - Article

VL - 39

SP - 489

EP - 495

JO - Antimicrobial Agents and Chemotherapy

T2 - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 2

ER -